00719.HK
Shandong Xinhua Pharmaceutical Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 5.65
+0.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.4B | 8.8B | 8.5B | 8.1B | 7.5B |
| Cost of Revenue | 6.9B | 7.1B | 6.4B | 5.8B | 5.5B |
| Gross Profit | 1.5B | 1.6B | 2.0B | 2.3B | 2.0B |
| Operating Expenses | |||||
| R&D Expense | 363.9M | 440.2M | 413.2M | 419.2M | 345.7M |
| SG&A Expense | 749.0M | 340.8M | 607.6M | 1.3B | 814.9M |
| General & Admin Expense | (109.5M) | 122.4M | 141.9M | 506.9M | 156.6M |
| Selling & Marketing Expense | 51.7M | 218.4M | 465.7M | 780.2M | 658.3M |
| Other Expenses | 193.7M | 447.3M | 486.4M | 69.7M | 333.4M |
| Total Operating Expenses | 1.2B | 1.2B | 1.5B | 1.8B | 1.5B |
| Cost and Expenses | 8.2B | 8.4B | 7.9B | 7.6B | 7.0B |
| Operating Income (EBIT) | 275.9M | 364.0M | 534.4M | 534.6M | 476.7M |
| Non-Operating | |||||
| Interest Income | 12.9M | 7.5M | 11.1M | 9.4M | 10.5M |
| Interest Expense | 37.9M | 43.3M | 39.7M | 41.1M | 49.7M |
| Net Interest Income | (28.3M) | (35.8M) | (31.2M) | (31.8M) | (42.6M) |
| Other Non-Op Income/Expense | (16.6M) | (5.1M) | (717.2K) | (1.9M) | (4.9M) |
| Non-Operating Income (excl Interest) | (33.7M) | 6.3M | (39.0M) | (39.3M) | (44.8M) |
| EBT (Pre-Tax Income) | 259.3M | 358.9M | 533.7M | 532.7M | 471.8M |
| Income Tax Expense | 37.1M | 52.6M | 46.9M | 26.6M | 45.5M |
| Bottom Line | |||||
| Net Income | 214.5M | 289.9M | 470.0M | 496.5M | 411.1M |
| Earnings from Cont. Ops | 222.2M | 306.3M | 486.7M | 506.1M | 426.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 214.5M | 289.9M | 470.0M | 496.5M | 411.1M |
| Per Share | |||||
| Basic EPS | HK$0.31 | HK$0.42 | HK$0.69 | HK$0.72 | HK$0.62 |
| Diluted EPS | HK$0.31 | HK$0.42 | HK$0.69 | HK$0.72 | HK$0.61 |
| Revenue Per Share | HK$12.11 | HK$12.70 | HK$12.41 | HK$11.75 | HK$11.31 |
| Shares | |||||
| Basic Shares Outstanding | 696.7M | 689.5M | 682.4M | 689.6M | 663.2M |
| Diluted Shares Outstanding | 696.7M | 691.6M | 682.4M | 691.9M | 674.1M |
| Profitability Metrics | |||||
| EBITDA | 437.5M | 988.9M | 1.1B | 1.1B | 1.0B |
| D&A | 320.2M | 587.5M | 540.9M | 516.9M | 484.8M |
| EBIT | 285.4M | 401.3M | 573.4M | 573.8M | 521.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026